UCB’s Bimekizumab Gets Fast-Track Funding For Severe Psoriasis In England
New HTA Route For “Low-Risk” Products Offers Rapid Patient Access
It may not yet be approved for marketing, but UCB’s potential blockbuster psoriasis drug has already got the all-clear from NICE, the health technology body that appraises new products for use in England and Wales.
You may also be interested in...
Bimzelx, which is expected to make a big splash in the psoriasis market, received its two marketing authorizations just days apart.
The psoriasis market is a tough one for bimekizumab to crack but UCB head of immunology Emmanuel Caeymaex believes the clinical package and investment in promotion will see the IL-17A and IL-17F inhibitor topple its rivals.
A gene therapy for multiple myeloma, a new drug for achondroplasia, and the first biosimilar version of Roche’s Lucentis are among eight products recommended for EU marketing authorization this week.